Does CLNN pay a dividend and is it safe?

Clene Inc. (CLNN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / CLNN / dividends

IBIO (23) HOWL (42) PLRX (34) RFL (16) ⌘ Pro Terminal →

Clene Inc. (CLNN) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.61 -5.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.57

Clene Inc. (CLNN) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $51.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLNN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Clene Inc. (NASDAQ: CLNN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $3.61 (-5.74% 1D, market cap $51.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CLNN ranks #912 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLNN compare to IBIO and HOWL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLNN carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of -35.0%. By comparison, IBIO (iBio Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $51.4M) and HOWL (Werewolf Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $51.0M). Among the 5-stock peer group, CLNN leads on earnings multiple (N/A) while CLNN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLNN?

▼

Per CLNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001822791), Clene Inc. generated $200.0K in revenue (-41.5% YoY), -$26.2M in net income, and -$18.6M in free cash flow against $18.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.57 (-1.22%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLNN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (26/100 Composite)

🔍 WHY CLNN SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (27% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 42.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 15.7% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.39+10% Next Q

Q2 (-2Q)

Grade E$3.73+6.4% Next Q

Q3 (-1Q)

Grade E$3.97-9.1% Next Q

Current

Grade E$3.61-10.5% Hist 90D α

Trajectory: E (18) → E (26)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLNN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLNN currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.93) and Max Pain ($3.79) forces dealer call-delta covering toward $14.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLNN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CLNN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 26%NO 74%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLNN)

✓Walkthrough of CLNN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CLNN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -45.14%⚡ TESTING RESISTANCE

2026-11-04O $3.83H $3.83L $3.61C $3.61VOL 54.0K

RES: $3.94SUP: $2.18SMA50: $3.93SMA200: $5.17

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLNN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLNN Butterfly Map → + Track CLNN →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -41.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CLNN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLNN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CLNN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLNN)

Health Care Rank #912 of 1015 ⚔️ IBIO vs CLNN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLNN vs. IBIO, HOWL, PLRX, RFL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Clene Inc. (CLNN) ranks #912 by composite RQD confidence (26/100, grade E) and #741 by equity capitalization ($51.3M). Within this direct 5-issuer industry benchmark cohort, CLNN leads on earnings valuation at N/A trailing P/E, while CLNN leads on capital efficiency and profitability with -35.0% ROIC and 78.5% gross margin. HOWL currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with CLNN at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CLNN ACTIVE Clene Inc.	E	26/100	—	78.5%	-35.0%	-5.74%	$51.3M	Benchmark Subject
IBIO iBio Inc.	E	23/100	—	—	-35.0%	+4.06%	$51.4M	/ibio-vs-clnn →
HOWL Werewolf Therapeutics Inc.	D-	42/100	—	—	-35.0%	+6.48%	$51.0M	/howl-vs-clnn →
PLRX Pliant Therapeutics Inc.	E	34/100	—	—	-35.0%	-2.29%	$52.0M	/plrx-vs-clnn →
RFL Rafael Holdings Inc. (Class B)	E	16/100	—	—	-35.0%	-7.41%	$52.2M	/rfl-vs-clnn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001822791 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Clene Inc. (CLNN) reported GAAP revenue of $200.0K (-41.5% vs. FY2024 revenue of $342.0K , and -69.4% cumulative change since FY2023) , GAAP net income of -$26.2M, operating cash flow of -$18.5M, and free cash flow of -$18.6M (+12.9% YoY). On the balance sheet, CLNN closed FY2025 with $18.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$200.0K	-$26.2M	-$18.5M	-$18.6M	$18.1M	—
FY2024 (FY)	2024-12-31	$342.0K	-$39.4M	-$21.3M	-$21.3M	$27.3M	—
FY2023 (FY)	2023-12-31	$654.0K	-$49.5M	-$30.2M	-$30.2M	—	—

3. CLNN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CLNN compare to IBIO and HOWL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CLNN?

Where is CLNN trading relative to its 50-day, 200-day, and 52-week technical levels?

CLNN last traded at $3.61 (-5.74% on volume of 54,019 shares), positioning the stock -8.14% below its 50-day simple moving average ($3.93) and -30.17% below its 200-day simple moving average ($5.17). Across its 52-week range of $3.02 to $13.50, CLNN sits at the 5.6% percentile with a 14-day RSI of 42.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.16 to $4.06).

Direct Sub-Reports: CLNN RQD Cockpit CLNN 12M Forecast CLNN Earnings & Move CLNN Dividends & DRIP CLNN Insiders & 13F CLNN Whale Options CLNN Profit Sankey CLNN News & Why

ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ SEC XBRL & RQD VERIFIED

CLNN — Clene Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Clene Inc. (CLNN) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.61 (-5.74% 1D, market capitalization $51.3M).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 78.5%, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Clene Inc. (CLNN) is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. Reported revenue is small, at $0.2M for FY 2025. Per the news wire, the company has an application seeking accelerated approval for an ALS drug, submitted in October.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Clene Inc. (CLNN) reported $200.0K in annual revenue (up from $342.0K in FY2024, -41.5% YoY) and -$26.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($654.0K revenue, -$49.5M net income) through FY2025, CLNN scaled operating cash flow to -$18.5M and free cash flow to -$18.6M, backed by $18.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $3.02 – $13.50 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector-level fact available is the Health Care / Pharmaceutical Preparations classification. A prospective investor should watch whether the ALS accelerated-approval application advances, since regulatory outcome is the most direct 2nd-order driver evident in the news wire.

Key Question #1: Can CLNN sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $200.0K and free cash flow of -$18.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is CLNN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CLNN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Clene Inc. (CLNN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLNN Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 1d ago

Clene(CLNN) Stock Options Chain | Quotes & News

Moomoo report covering Clene Inc. (CLNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

The CFO receives 20,000 Clene (CLNN) stock options with a $3.73 exercise price.

Stock Titan report covering Clene Inc. (CLNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Clene (NasdaqCM:CLNN) Stock Forecast & Analyst Predictions

Simply Wall St report covering Clene Inc. (CLNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 2d ago

Clene Inc. (CLNN) Slides 2.88% to $3.75 as Shares Approach Key Support - AAII Neutral

https://www.siam.in/ report covering Clene Inc. (CLNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 2d ago

An application seeks accelerated approval for Clene’s ALS drug. It was submitted in October.

Stock Titan report covering Clene Inc. (CLNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 2d ago

Clene Inc. (CLNN) Holds Steady at $3.88 as Traders Eye Resistance - Hedge Fund Favorites

https://www.dars.gov.et/ report covering Clene Inc. (CLNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 2d ago

A 30,000-option grant for Clene (CLNN)'s science chief carries a $3.73 exercise price.

Stock Titan report covering Clene Inc. (CLNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.siam.in/ • 2d ago

Clene Inc. (CLNN) Slips 0.52% to $3.86, Holding Above $3.67 Support - Bearish Pattern Stocks

https://www.siam.in/ report covering Clene Inc. (CLNN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLNN Bull vs. Bear Conversation Board — What's Your Call at $3.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLNN 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $4.52 (+18.0%)

📌 Pinned Debate

The ALS drug accelerated-approval application submitted in October is a potential regulatory catalyst that could re-rate a stock tradin

Here is why I am bullish on CLNN here at $3.83: The ALS drug accelerated-approval application submitted in October is a potential regulatory catalyst that could re-rate a stock trading 72% below its 52-week high.. Compare CLNN's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $3.64 are getting bought.

ArenaChamp_24 🐂 BULL

@DeltaGamma_99 Agree on the RQD 26/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.83 and keeping dry powder in case we test $3.56.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $3.18 (-17.0%)

Spot @ $3.83

With ROIC at -35%, FCF yield at 0%, a 3/20 insider-conviction pillar, and cash falling to $5.2M, the company shows weak cash generation

Careful chasing CLNN at $3.83. With ROIC at -35%, FCF yield at 0%, a 3/20 insider-conviction pillar, and cash falling to $5.2M, the company shows weak cash generation and limited balance-sheet cushion.. Gross margin is 78.5%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $3.18 on multiple compression.